HC Wainwright Issues Negative Outlook for AARD Earnings

Aardvark Therapeutics, Inc. (NASDAQ:AARD) – Investment analysts at HC Wainwright decreased their Q2 2026 earnings per share (EPS) estimates for Aardvark Therapeutics in a research report issued on Monday, July 20th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($1.05) for the quarter, down from their prior forecast of ($0.95). HC Wainwright currently has a “Neutral” rating and a $6.00 price target on the stock. The consensus estimate for Aardvark Therapeutics’ current full-year earnings is ($3.48) per share. HC Wainwright also issued estimates for Aardvark Therapeutics’ Q3 2026 earnings at ($0.94) EPS, Q4 2026 earnings at ($0.82) EPS, FY2026 earnings at ($3.80) EPS, Q1 2027 earnings at ($0.72) EPS, Q2 2027 earnings at ($0.55) EPS, Q3 2027 earnings at ($0.42) EPS and Q4 2027 earnings at ($0.35) EPS.

Other analysts have also recently issued reports about the stock. Weiss Ratings raised shares of Aardvark Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 2nd. Morgan Stanley reaffirmed an “underweight” rating and issued a $3.00 price objective (down from $7.00) on shares of Aardvark Therapeutics in a research report on Friday, May 15th. BTIG Research downgraded Aardvark Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 15th. Finally, B. Riley Financial decreased their price target on Aardvark Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Friday, May 15th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Aardvark Therapeutics has a consensus rating of “Hold” and a consensus price target of $16.30.

Aardvark Therapeutics Price Performance

Shares of NASDAQ AARD opened at $6.48 on Wednesday. The company has a 50-day simple moving average of $4.82 and a 200-day simple moving average of $7.37. The company has a market cap of $141.78 million, a PE ratio of -2.02 and a beta of 3.93. Aardvark Therapeutics has a 12 month low of $3.35 and a 12 month high of $17.94.

Aardvark Therapeutics (NASDAQ:AARD) last announced its earnings results on Thursday, May 7th. The company reported ($0.99) earnings per share for the quarter.

Institutional Trading of Aardvark Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Goldman Sachs Group Inc. purchased a new position in shares of Aardvark Therapeutics in the 1st quarter worth $153,000. Geode Capital Management LLC grew its position in Aardvark Therapeutics by 129.7% during the second quarter. Geode Capital Management LLC now owns 136,927 shares of the company’s stock valued at $1,851,000 after acquiring an additional 77,327 shares during the period. New York State Common Retirement Fund acquired a new stake in Aardvark Therapeutics during the second quarter worth about $99,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Aardvark Therapeutics in the 2nd quarter worth about $42,000. Finally, Bank of America Corp DE raised its holdings in shares of Aardvark Therapeutics by 72.9% in the 2nd quarter. Bank of America Corp DE now owns 7,989 shares of the company’s stock worth $108,000 after purchasing an additional 3,369 shares during the period.

Key Aardvark Therapeutics News

Here are the key news stories impacting Aardvark Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a Neutral rating and $6.00 price target on Aardvark Therapeutics, while issuing earnings estimates for 2026-2027. The firm also nudged its Q4 2026 EPS estimate higher, which may have helped sentiment around the stock. MarketBeat AARD report
• Neutral Sentiment: HC Wainwright’s forecasts still point to continuing losses over the next several quarters, with FY2026 EPS estimated at ($3.80) and FY2027 at ($1.98), underscoring that Aardvark remains a pre-profit biotech story. MarketBeat AARD report
• Negative Sentiment: Investor focus is still being weighed down by the FDA clinical hold on Aardvark’s lead Prader-Willi Syndrome candidate, a development that previously triggered a sharp selloff and continues to create uncertainty around the company’s pipeline. PR Newswire article

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.